PARIS, November 13, 2024--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In the rapidly advancing field of novel therapies, especially in areas like cell and gene therapies, ensuring rigorous ...

In a report released on November 13, Justine Telliez from Kepler Capital maintained a Hold rating on GenSight Biologics SA (G49N – ...

1 Day GSGTF 0.00% DJIA 0.76% Russell 2K 1.54% Health Care/Life Sciences -0.41% ...

GenSight Biologics is weeks away from running out of money. Again. The biotech only has enough cash to fund operations into mid-November and, with a revenue stream set to start later than planned ...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a ...

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative ...

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases ...

PARIS, October 17, 2024--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing ...